Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy

被引：14
|
作者：
Korte, W
Jost, C
Cogliatti, S
Hess, U
Cerny, T [1 ]
机构：
[1] Kantonsspital, Div Med Oncol, CH-9007 St Gallen, Switzerland
[2] Kantonsspital, Inst Clin Chem & Haematol, CH-9007 St Gallen, Switzerland
[3] Kantonsspital, Inst Pathol, CH-9007 St Gallen, Switzerland
来源：
ANNALS OF ONCOLOGY | 1999年 / 10卷 / 10期
关键词：
CD20; IL-6; monitoring; multiple myeloma;
D O I：
10.1023/A:1008310819049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1249 / 1250
页数：2
相关论文
共 50 条
  • [1] Anti-CD20 monoclonal antibody therapy in multiple myeloma
    Kapoor, Prashant
    Greipp, Patricia T.
    Morice, William G.
    Rajkumar, S. Vincent
    Witzig, Thomas E.
    Greipp, Philip R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) : 135 - 148
  • [2] Development of anti-CD20 therapy for multiple sclerosis
    Bartok, Beatrix
    Silverman, Gregg J. J.
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1312 - 1318
  • [3] Anti-CD20 (rituximab) in follicular lymphoma
    McLaughlin, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S51 - S51
  • [4] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
    Witzens, M
    Gemmel, C
    Moos, M
    Goldschmidt, H
    Ho, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
  • [5] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Michael Zhong
    Anneke van der Walt
    Maria Pia Campagna
    Jim Stankovich
    Helmut Butzkueven
    Vilija Jokubaitis
    Neurotherapeutics, 2020, 17 : 1768 - 1784
  • [6] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Zhong, Michael
    van der Walt, Anneke
    Campagna, Maria Pia
    Stankovich, Jim
    Butzkueven, Helmut
    Jokubaitis, Vilija
    NEUROTHERAPEUTICS, 2020, 17 (04) : 1768 - 1784
  • [7] Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab
    Chen, Lucia Y.
    Shah, Raakhee
    Cwynarski, Kate
    Lambert, Jonathan
    McNamara, Christopher
    Mohamedbhai, Sajir G.
    Virchis, Andres
    Townsend, William
    D'Sa, Shirley
    Ardeshna, Kirit M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 462 - 465
  • [8] Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)
    Morrison, LH
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (05) : 817 - 819
  • [9] Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myocionus syndrome
    Pranzatelli, Michael R.
    Tate, Elizabeth D.
    Travelstead, Anna L.
    Barbosa, Jerry
    Bergamini, Robert A.
    Civitello, Lucy
    Franz, David N.
    Greffe, Brian S.
    Hanson, Robin D.
    Hurwitz, Craig A.
    Kalinyak, Karen A.
    Fer, Howard Ke
    Khakoo, Yasmin
    Mantovani, John F.
    Nicholson, Stacy H.
    Sanders, Joann M.
    Wegner, Stephen
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (09) : 585 - 593
  • [10] B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
    Shaw, T
    Quan, J
    Totoritis, MC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 55 - 59
12345